Paxman AB (PAX) AI Stock Analysis

• Market Cap: kr1.73B
• Dividend Yield: N/A
• Average Volume (3M): 26.46K
• Price to Earnings (P/E): 156.8
• Beta (1Y): 0.31
• Revenue Growth: 14.28%
• EPS Growth: -68.33%
• Country: SE
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 23,273,417
• 10 Day Avg. Volume: 29,065
• 30 Day Avg. Volume: 26,460
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr79.95
• Price Target Upside: 7.47% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: kr80.00 ▲(7.53% Upside)

Paxman AB's overall stock score is driven primarily by its strong financial performance, characterized by revenue growth and a robust balance sheet. However, the high P/E ratio indicates potential overvaluation, and technical indicators suggest a lack of strong momentum. The absence of earnings call data and corporate events means these factors do not influence the score.

Paxman AB Business Overview & Revenue Model

Company Description

Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.

How the Company Makes Money

Paxman AB generates revenue primarily through the sale and leasing of its scalp cooling systems to hospitals and outpatient clinics. The company employs a dual revenue model that includes direct sales of equipment and recurring revenue from the sale of consumables, such as cooling caps, which are integral to the system's operation. Additionally, Paxman may receive revenue from service contracts for the maintenance and support of their equipment. Significant partnerships with healthcare providers and oncology clinics enhance Paxman's market reach and contribute to its earnings by facilitating wide adoption of its technology in cancer care.

Paxman AB Financial Statement Overview

Summary

Paxman AB exhibits strong financial health with significant revenue growth and improved profitability metrics. The balance sheet is solid with low leverage, and cash flow statements show positive trends. Continued focus on cost management and monitoring liabilities will be key to sustaining this positive trajectory.

Income Statement

Paxman AB has demonstrated strong revenue growth with a significant increase from 2020 to TTM 2025. Gross profit margins have remained robust, reflecting efficient cost management. The net profit margin has improved from negative in 2020 to a healthy positive margin in TTM 2025, indicating enhanced profitability. However, the slight decline in gross profit in TTM compared to 2024 suggests potential cost challenges.

Balance Sheet

The company's balance sheet shows a favorable debt-to-equity ratio, indicating low leverage and financial stability. The equity ratio remains strong, suggesting a solid asset base supported by equity. Return on Equity has improved significantly, showcasing effective use of shareholders' funds. Nonetheless, the increase in total liabilities from 2024 to TTM 2025 requires monitoring.

Cash Flow

Paxman AB shows strong operating cash flows and positive free cash flow, indicating good cash generation capabilities. The company has managed to maintain a positive free cash flow despite capital expenditures. The operating cash flow to net income ratio reflects efficient cash management, though the decline in free cash flow growth from 2024 to TTM 2025 needs attention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	261.52M	253.01M	210.12M	156.75M	96.20M	78.05M
Gross Profit	145.36M	175.42M	146.42M	101.44M	64.52M	50.69M
EBITDA	55.17M	49.73M	31.23M	16.18M	2.90M	-1.04M
Net Income	21.49M	40.20M	8.33M	-10.32M	-12.78M	-19.19M
Balance Sheet
Total Assets	321.21M	227.23M	167.12M	173.96M	166.34M	77.01M
Cash, Cash Equivalents and Short-Term Investments	152.72M	40.31M	24.98M	38.09M	72.27M	3.58M
Total Debt	9.54M	14.29M	13.57M	16.98M	17.15M	48.23M
Total Liabilities	45.25M	63.24M	44.51M	59.76M	40.59M	66.12M
Stockholders Equity	275.97M	163.99M	122.62M	114.20M	125.75M	10.89M
Cash Flow
Free Cash Flow	15.79M	15.99M	-9.70M	-33.01M	-27.94M	-14.80M
Operating Cash Flow	35.20M	39.10M	15.63M	2.69M	-4.14M	-8.48M
Investing Cash Flow	-19.45M	-24.50M	-25.33M	-36.69M	-24.45M	-6.32M
Financing Cash Flow	109.63M	721.00K	-3.41M	-169.00K	97.28M	16.78M

Paxman AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 74.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PAX, the sentiment is Negative. The current price of 74.4 is below the 20-day moving average (MA) of 75.44, below the 50-day MA of 77.60, and above the 200-day MA of 72.72, indicating a neutral trend. The MACD of -0.58 indicates Positive momentum. The RSI at 44.57 is Neutral, neither overbought nor oversold. The STOCH value of 11.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PAX.

Paxman AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAX	62 Neutral	kr1.73B	156.78	2.64%	―	14.28%	-68.33%
CRAD.B	62 Neutral	1.02B	39.79	7.56%	―	-10.34%	-59.69%
OSSD	57 Neutral	1.65B	-33.09	-23.20%	―	36.23%	63.14%
SEZI	51 Neutral	974.73M	-6.59	-34.03%	―	71.41%	17.26%
BRAIN	50 Neutral	227.04M	-5.99	0.00%	―	18.37%	34.23%
SEDANA	48 Neutral	1.36B	-26.65	-5.53%	―	16.27%	-22.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%